About APIM Therapeutics
APIM Therapeutics is a Healthcare company based in Trondheim (Norway) founded in 2009. Developer of anti-cancer therapies potentiating chemotherapy induced responses in cancer cells. APIM Therapeutics has raised $3.56 million across 5 funding rounds from investors including Berg Capital Group, Investinor and Sarsia Seed. The company has 1 employees. APIM Therapeutics offers products and services including ATX-101 and Peptide Drugs Pipeline. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its legal entity is APIM Therapeutics AS.
Company details
APIM Therapeutics was founded in 2009 in Trondheim, Norway, within the biotechnology sector. Anti-cancer therapies are developed to potentiate chemotherapy-induced responses in cancer cells through a pipeline of peptide drugs. These target PCNA-dependent stress responses, with PCNA serving as a regulator of DNA replication, repair, and cell cycle control. The flagship candidate, ATX-101, has demonstrated proof-of-concept in animal models for blood and solid tumors.
- Headquarters Trondheim, Norway
- Employees 1
- SectorsHealthcare
- Email••••••••
- Website apimtherapeutics.com
- Social LinkedIn
- Legal Name Apim Therapeutics As
- Annual Revenue$10.86 K (USD)as on Dec 31, 2022
- Net Profit-$2.75 M (USD)-78as on Dec 31, 2022
- EBITDA-$2.75 M (USD)-78as on Dec 31, 2022
- Total Equity Funding$3.56M (USD)
in 5 rounds
- InvestorsBerg Capital Group
& 4 more
- Employee Count1
Products & Services of APIM Therapeutics
APIM Therapeutics offers a comprehensive portfolio of products and services, including ATX-101 and Peptide Drugs Pipeline.
Peptide drug targeting stress responses in cancer cells for treatment.
Pipeline of drugs addressing cancer stress responses in clinical settings.
Funding Insights of APIM Therapeutics
APIM Therapeutics has successfully raised a total of $3.56M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.56M
- Total Rounds 5
- First Round $556,000
(May 2010)
- Investors Count 5
All 5 funding rounds of APIM Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | Series A | – | – | – | |
| Dec 2017 | $3M | Series A | – | Sarsia Seed | |
| Oct 2012 | Series A | – | – | ||
| Nov 2011 | Series A | – | – | ||
| May 2010 | $556,000 | Seed | – | – |
5 investors in total: 5 institutional.
Investors in APIM Therapeutics
APIM Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Berg Capital Group, Investinor and Sarsia Seed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| bergcapitalgroup.com | ||||
| investinor.no | ||||
| sarsiaseed.com | ||||
Televenture is recognized as a leading venture capital firm in Norway. | 1993 | televenture.no | Oslo, Norway | |
| birkventure.no |
Investor details for APIM Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of APIM Therapeutics
10 people are tracked at APIM Therapeutics (3 in leadership, 7 in board & advisors); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Kostas Alevizopoulos | Chief Executive Officer | Leadership |
Marit Otterlei | Chief Scientific Officer | Leadership |
Hans Olav Minsås | Chief Financial Officer | Leadership |
Erlend Skagseth | Chairman | Board & advisors |
Stener Kvinnsland | Board Member | Board & advisors |
Farzad Abdi-Dezfuli | Board Member | Board & advisors |
Jørgen André Nilsen | Board Member | Board & advisors |
Martin Welschof | Board Member | Board & advisors |
Birgitte Gangmark Villmo | Board Member | Board & advisors |
Gökhan Batur | Board Member | Board & advisors |
Complete people profiles for APIM Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of APIM Therapeutics
3 dated milestones of APIM Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded APIM Therapeutics is founded.
- Funding First funding round of $556K.
- Funding Latest funding round, Series A,.
Web traffic of APIM Therapeutics
The website of APIM Therapeutics (apimtherapeutics.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 95.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apim Therapeutics
Complete news archive for APIM Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about APIM Therapeutics
APIM Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
APIM Therapeutics is headquartered in Trondheim, Norway. It is registered at Trondheim, Trøndelag, Norway.
APIM Therapeutics is a funded company, having raised a total of $3.56M across 5 funding rounds to date. The company's 1st funding round was a Seed of $556K, raised on May 2010.
APIM Therapeutics has 1 employees.
Annual revenue of APIM Therapeutics is $10.86K as on Dec 31, 2022.
APIM Therapeutics was founded in 2009 in Trondheim, Norway, within the biotechnology sector. Anti-cancer therapies are developed to potentiate chemotherapy-induced responses in cancer cells through a pipeline of peptide drugs. These target PCNA-dependent stress responses, with PCNA serving as a regulator of DNA replication, repair, and cell cycle control. The flagship candidate, ATX-101, has demonstrated proof-of-concept in animal models for blood and solid tumors.
APIM Therapeutics offers ATX-101 and Peptide Drugs Pipeline.
APIM Therapeutics has 5 investors. Key investors include Berg Capital Group, Investinor, Sarsia Seed, Televenture, and Birk Venture.
APIM Therapeutics operates through Apim Therapeutics As.